Stay updated with breaking news from Scientific Rationale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S.
Olatec Therapeutics, Inc. (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson's granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow...
Just prior to B.C. scrapping plans to mandate COVID-19 vaccination for all regulated health professionals, a group of ...